Mirabegron - 'first-in-class' medicine

Order Description Please use authoritative journal articles only. There may only be a few on it so if not able to find 8 that is fine. Mirabegron is a 'first-in-class' medicine approved for management of overactive bladder syndrome. (Chappel et al. 2014). More recently, regulatory authorities have stated concern based on emerging reports of adverse effects (Mirabegron (Betmiga) Medicines and Healthcare Products Regulatory Agency,2015). Describe pharmacology(including pharmacokinetics, drug metabolism, pharmacodynamics) of Mirabegron. Discuss concepts of 'selectivity' and 'drug target' in relation to mirabegron. Describe adverse effects and contraindications. Develop hypothesis or hypotheses for cardiovascular effects. Section 1: Abstract maximum 250 words. Prepare as a single paragraph summarising main points of argument. Imperative to capture the interest of the reader. Section 2: main argument ( 1500 words max, excluding references, figures, figure legends and tables.) be concise, informative and authoritative. Include appropriate subheadings to help reader. Label figuresand tables etc 'Figure1, Table 1 etc Reference in the body of text at the end of the sentence.